1. Academic Validation
  2. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators

The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators

  • Oncogene. 1999 Jun 3;18(22):3316-23. doi: 10.1038/sj.onc.1202717.
R Dechend 1 F Hirano K Lehmann V Heissmeyer S Ansieau F G Wulczyn C Scheidereit A Leutz
Affiliations

Affiliation

  • 1 Max-Delbrück-Center for Molecular Medicine MDC, Berlin.
Abstract

The proto-oncoprotein Bcl-3 is a member of the IkappaB family and is present predominantly in the nucleus. To gain insight into specific nuclear functions of Bcl-3 we have isolated proteins that interact with its ankyrin repeat domain. Using the yeast two-hybrid-system we identified four novel binding partners of Bcl-3 in addition to NF-kappaB p50 and p52, previously known to associate with Bcl-3. The novel Bcl-3 interactors Jab1, Pirin, TIP60 and Bard1 are nuclear proteins which also bind to Other transcription factors including c-Jun, nuclear factor I (NFI), HIV-1 Tat or the tumor suppressor and PolII holoenzyme component Brca1, respectively. Bcl-3, p50, and either Bard1, TIP60 or Pirin are sequestered into quarternary complexes on NF-kappaB DNA binding sites, whereas Jab1 enhances p50-Bcl-3-DNA complex formation. Furthermore, the histone acetylase TIP60 enhances Bcl-3-p50 activated transcription through an NF-kappaB binding site, indicating that quarternary complexes containing Bcl-3 interactors modulate NF-kappaB driven gene expression. These data implicate Bcl-3 as an adaptor between NF-kappaB p50/p52 and Other transcription regulators and suggest that its gene activation function may at least in part be due to recruitment of the TIP60 histone actetylase.

Figures